← All trials

NCT06923072

Phase 2Interventional

Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

View on ClinicalTrials.gov ↗

Timeline

Start date
Dec 2, 2025
Primary completion
Dec 14, 2030
Completion date
Dec 15, 2030
First posted
Apr 11, 2025
Last posted
Nov 28, 2025
Enrollment
12
Arms / groups
1 / —
Source
AACT · ctgov ingestion

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.